![]() |
|
|
Vol. 281, Issue 1, 491-498, 1997
Laboratoire de Pharmacologie (A.C., J.J.S., G.C.), Faculté de
Pharmacie, Montpellier, France and
Institut Universitaire de Recherche
Clinique (F.G.), Molecular Endocrinology, Montpellier, France
In order to explore the mechanism of action of vanadyl sulfate
(VOSO4), previously described as an antidiabetic and
antihypertensive agent, we have investigated the role of calcium and
tyrosine phosphorylation in the contractile responses of rat aorta or
skinned rabbit mesenteric artery rings. VOSO4 induced a
concentration-dependent contraction of aorta (pD2 = 3.2),
which was potentiated by endothelium removal (pD2 = 4.2).
After a first exposure to VOSO4, no change in
responsiveness was observed even though high vanadium concentrations
had accumulated in the aortic tissue (
4 × 10
3
M). VOSO4 induced, in calcium-free medium, a significant
response that, relative to contractions measured in Krebs-Henseleit
buffer, was higher (36%) than norepinephrine (16%)-,
arginine-vasopressin (8%)- or KCl (5%)-induced responses.
8-(N,N-diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride
(TMB-8), an intracellular calcium release inhibitor, did not modify
VOSO4-induced response either in the presence or in the
absence of ambient calcium. On skinned preparations, VOSO4
antagonized Ca++-induced contraction. The tyrosine kinase
inhibitors tyrphostin 23 (T23) and tyrphostin 47 (T47) potentiated by 4- and 14-fold, respectively, the
activity of VOSO4, in contrast to the lack of effect of
T47 on pervanadate-induced contraction. When
phosphotyrosine content was revealed by Western blotting,
VOSO4 had no effect alone, but in the presence of
T47, it dramatically increased the phosphotyrosine content.
This result contrasts again with PV-induced tyrosine phosphorylation,
which was blocked by T47. These data suggest that the
signaling events involved in vascular effects of VOSO4,
although they depend little on calcium mobilization, are related to
tyrosine phosphorylation, likewise through a pathway different from
that of pervanadate.